Stocktoria
Jazz Pharmaceuticals plc JAZZ
Nasdaq · XNAS · stock · Pharmaceutical Preparations · website · IPO 2012-01-18
Jazz Pharmaceuticals plc financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $4.3B | $4.1B | $3.8B | $3.7B | $3.1B |
| SG&A expense | $1.8B | $1.4B | $1.3B | $1.4B | $1.5B |
| Operating income | -$430.2M | $716.6M | $578.6M | -$65.5M | $170.3M |
| Income tax | -$272.4M | -$91.4M | -$119.9M | -$158.6M | $216.1M |
| Net income | -$356.1M | $560.1M | $414.8M | -$224.1M | -$329.7M |
| EPS (diluted) | $-5.84 | $8.65 | $6.10 | $-3.58 | $-5.52 |
| Operating cash flow | $1.4B | $1.4B | $1.1B | $1.3B | $778.5M |
| Free cash flow | $1.3B | $1.4B | $1.1B | $1.2B | $750.9M |
| Cash & equivalents | $1.4B | $2.4B | $1.5B | $881.5M | $591.4M |
| Inventory | $417.0M | $480.4M | $597.0M | $714.1M | $1.1B |
| Total assets | $11.7B | $12.0B | $11.4B | $10.8B | $12.3B |
| Shareholders' equity | $4.3B | $4.1B | $3.7B | $3.1B | $4.0B |
Source: SEC EDGAR filings · CIK 0001232524 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.